Management of Type 2 Diabetes
Especially in those patients who require improvement in glycemic control.
Dipetor contains linagliptin, a DPP-4 inhibitor for oral administration. It is used to improve glycemic control in adults with type 2 diabetes mellitus and does not require dose adjustment in patients with renal impairment. By inhibiting the DPP-4 enzyme, linagliptin increases incretin activity, helping enhance glucose-dependent insulin secretion and reduce glucagon levels.
Dipetor is indicated for the treatment of adults with type 2 diabetes to improve blood glucose control as part of a comprehensive plan that includes diet and exercise. It is suitable for use in the following cases:
Especially in those patients who require improvement in glycemic control.
It can be used in combination with other diabetes medications when monotherapy with Linagliptin is not sufficient.
Helps improve glycemic control in adults with type 2 diabetes as an adjunct to diet and exercise.
Linagliptin is a potent selective inhibitor of the DPP-4 enzyme that prolongs the activity of incretin hormones.
It increases insulin secretion and decreases glucagon production in the presence of elevated glucose.
Effective in controlling basal and postprandial glucose.
How Dipetor works
Dipetor®Linagliptinin the presence of elevated glucose
Basal & postprandial glucose controlDipetor contains linagliptin, a DPP-4 inhibitor for oral administration. It is used to improve glycemic control in adults with type 2 diabetes mellitus and does not require dose adjustment in patients with renal impairment. By inhibiting the DPP-4 enzyme, linagliptin increases incretin activity, helping enhance glucose-dependent insulin secretion and reduce glucagon levels.
Dipetor is indicated for the treatment of adults with type 2 diabetes to improve blood glucose control as part of a comprehensive plan that includes diet and exercise. It can be used for the management of type 2 diabetes, in combination with other diabetes medications when monotherapy with Linagliptin is not sufficient, and to help improve glycemic control in adults with type 2 diabetes as an adjunct to diet and exercise.
Linagliptin is a potent selective inhibitor of the DPP-4 enzyme that prolongs the activity of incretin hormones. It increases insulin secretion and decreases glucagon production in the presence of elevated glucose, and is effective in controlling basal and postprandial glucose.
Dosing is simple and convenient: 5 mg once daily, regardless of meals. It can be taken at any time of day, but it is preferable to maintain a regular schedule.
Once-daily oral administration, which simplifies the treatment regimen and improves patient adherence. Effective on its own or in combination with other diabetes treatments, including metformin, sulfonylureas or insulin. Low risk of hypoglycemia and weight-neutral side effects.
Does not require dose adjustment based on age or renal function. Evaluate glycemic control regularly to adjust treatment as necessary. Ideal for patients with renal comorbidities since it is not significantly excreted by the kidneys.
Monitor for signs of pancreatitis and hypersensitivity reactions. Caution in patients with a history of pancreatic disease. Contraindicated in patients with a history of severe allergic reaction to linagliptin.
Dipetor contains linagliptin 5 mg and is presented in a box of 30 tablets, for oral administration.
Crassula Pharma certifies that all its products are manufactured in accordance with GMP parameters.
Crassula Pharma certifies that all our products are manufactured in accordance with GMP parameters.